[fusion_builder_container type="flex" hundred_percent="no" equal_height_columns="no" hide_on_mobile="small-visibility,medium-visibility,large-visibility" background_position="center center" background_repeat="no-repeat" fade="no" background_parallax="none" parallax_speed="0.3" video_aspect_ratio="16:9" video_loop="yes" video_mute="yes" border_style="solid"][fusion_builder_row][fusion_builder_column type="1_1" type="1_1" layout="1_1" background_position="left top" border_style="solid" border_position="all" spacing="yes" background_repeat="no-repeat" margin_top="0px" margin_bottom="0px" animation_speed="0.3" animation_direction="left" hide_on_mobile="small-visibility,medium-visibility,large-visibility" center_content="no" last="true" hover_type="none" background_blend_mode="overlay" first="true" min_height="" link=""][fusion_text] Coronavirus (COVID-19) Ritonavir-Boosted Nirmatrelvir Prescribing Information Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Medications The SARS-CoV-2 Monoclonal Antibody AZD3152 Potently Neutralizes Historical and Emerging Variants and is Being Developed for the Prevention and Treatment of COVID-19 in High-risk Individuals The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future Vaccines and therapeutics for immunocompromised patients with COVID-19 Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study The Evolving Role of the Rheumatology Practitioner in the Care of Immunocompromised Patients in the COVID-19 Era Long COVID: major findings, mechanisms and recommendations Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients The COVID-19 Pandemic Rages on for People Who Are Immunocompromised CDC: COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised IDSA and CDC COVID-19 Real-Time Learning Network: Immunocompromised Populations Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 NIH COVID-19 Treatment Guidelines: Therapeutic Management of Nonhospitalized Adults With COVID-19 <a href="https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fcovid19-druginteractions.org%2F&data=05%7C01%7Ctallvord%40vindicocme.com%7Cd00075f92e504152320d08da270a7a72%7Cda938b042dd64bbcbe65f6c4645153a1%7C0%7C0%7C637865223206459163%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=oT25M4s45mhTzvHffJhlbQvxPxYUL5cbPCKcyTNiqmY%3D&reserved=0" target="_blank" rel="noopener noreferrer">COVID-19 Drug Interactions Dexamethasone in Hospitalized Patients with Covid-19 IDSA Guidelines on the Treatment and Management of Patients with COVID-19 COVID-19 Real-Time Learning Network (IDSA) Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalized adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 NIH: Therapeutic Management of Hospitalized Adults With COVID-19 NIH COVID-19 Treatment Guidelines FDA COVID-19 Emergency Use Authorizations: Drug and Biological Therapeutic Products Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 (ACTT-2) Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19 (COV-BARRIER) Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY) CDC Coronavirus Disease 2019 (COVID-19) Resources WHO Resources: COVID-19 Pandemic Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 JAMA Patient Page: Oral antiviral medications for COVID-19 Molnupiravir EUA Nirmatrelvir EUA Gram-negative Bacterial Infections Gram-negative Bacteria Infections in Healthcare Settings IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 1.0 RESTORE-IMI 1: A Multicenter, Randomized, Double- blind Trial Comparing Efficacy and Safety of Imipenem/ Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial New Perspectives on Antimicrobial Agents: Cefiderocol Cytomegalovirus (CMV) Letermovir for Primary and Secondary CMV Prevention: Real-world experience Letermovir for Secondary Prophylaxis of CMV Infection Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation Cytomegalovirus (CMV) Infection About CMV for Patients Clinical manifestations, diagnosis, and management of CMV disease in kidney transplant recipients Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation Maribavir for Treatment of CVM Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic SCT or SOT Recipients Herpes Zoster Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines Efficacy and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older CDC: Shingles Vaccine Factsheet for Adult Patients CDC: Shingles Vaccine Factsheet for Health Care Professionals HIV Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV INSTI Drug Interactions HIV and Drug-resistance Testing Evidence-based Interventions to Improve HIV Medication Adherence Optimizing Antiretroviral Therapy in the Setting of Virologic Suppression Adherence to the Continuum of Care Drug-Drug Interactions Drug Database: Cabotegravir Women with HIV Adverse Effects of Antiretroviral Therapy Considerations for Antiretroviral Therapy in the Older Patient Stanford University HIV Drug Resistance Database Understanding HIV Laboratory Tests – for Patients NNRTI Drug Interactions NRTI Drug Interactions PI Drug Interactions Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents- Tables What to Start: Selecting a First HIV Regimen ViiV, J&J's Cabenuva gains FDA approval as long-acting regimen for HIV PrEP Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections Safety Review of TDF/FTC PrEP for Pregnant Women at Risk of HIV Infection On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection PrEP Resources in all 50 States National Clinician Consultation Center for PrEP Preexposure Prophylaxis for the Prevention of HIV Infection of the United States – 2021 Update Quick Guide: 2021 PrEP Update Pre-Exposure Prophylaxis (PrEP) HIV Prevention Materials for Your Practice Let's Stop HIV Together: HIV Prevention Drug information on cabotegravir Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women (HPTN 083) Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: results from HPTN 084 Influenza A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017–18 influenza season - ScienceDirect Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts Baloxavir Prescribing Information 2018 Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza Seasonal Influenza Vaccine Effectiveness Studies Influenza Antiviral Medications: Summary for Clinicians FDA-cleared Nucleic Acid Detection Based Tests for Influenza Viruses Information for Clinicians on Influenza Virus Testing What You Should Know About Influenza (Flu) Antiviral Drugs Diagnostic Accuracy of Novel and Traditional Rapid Tests for Influenza Infection Compared With Reverse Transcriptase Polymerase Chain Reaction Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents People at High Risk For Flu Complications Clinical Outcomes of Oseltamivir vs. Baloxavir in Patients Hospitalized with Influenza A Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children Early Treatment With Baloxavir Marboxil in High-Risk Adolescent and Adult Outpatients With Uncomplicated Influenza (CAPSTONE-2): A Randomised, Placebo-controlled, Phase 3 Trial Similarities and Differences between Flu and COVID-19 Invasive Fungal Infections CDC Fungal Diseases – Patient Information Information for Healthcare Professionals about Invasive Candidiasis Information for Healthcare Professionals about Mucormycosis Information for Healthcare Professionals about Aspergillosis Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America Isavuconazonium sulfate Prescribing Information New Concepts in Diagnostics for Invasive Mycoses: Non-Culture-Based Methodologies Molecular Diagnostics A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology Panels and Syndromic Testing in Clinical Microbiology Syndromic Panel-Based Testing in Clinical Microbiology New and novel rapid diagnostics that are impacting infection prevention and antimicrobial stewardship Advances in rapid diagnostics for bloodstream infections Diagnostic test accuracy of the BioFire® FilmArray® meningitis/encephalitis panel: a systematic review and meta-analysis Relationship of Multiplex Molecular Pneumonia Panel Results With Hospital Outcomes and Clinical Variables Enhanced Detection of Community-Acquired Pneumonia Pathogens With the BioFire® Pneumonia FilmArray® Panel Pediatrics Recommendations for Prevention and Control of Influenza in Children, 2022–2023 CDC Facts About Crypto and Swimming Pools – Patient Handout Cryptosporidiosis Giardiasis Swimming Pool Hygiene Facts About Crypto and Swimming Pools - Patient Handout Human Papillomavirus (HPV): The Need to Immunize - Patient Handout Pneumococcal Disease Advisory Committee on Immunization Practices (ACIP): Pneumococcal Vaccine Recommendations Updated ACIP Recommendations and Evidence Review: Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children Updated ACIP Recommendations and Evidence Review: Use of PCV15 and PCV20 Among US Adults Immunize.org Ask the Experts: Pneumococcal Vaccines for Children and Adults Pneumococcal Vaccination ACIP: Clinical Considerations for Use of PCV15 in Children AAFP: Simplifying Pneumococcal Immunizations for Adults Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults Association Between the Decline in Pneumococcal Disease in Unimmunized Adults and Vaccine-Derived Protection Against Colonization in Toddlers and Preschool-Aged Children Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001-2016 PneumoRecs VaxAdvisor Mobile App Racial Disparities in Adult Pneumococcal Vaccination Marked Reduction of Socioeconomic and Racial Disparities in Invasive Pneumococcal Disease Associated With Conjugate Pneumococcal Vaccines PCV15 Prescribing Information PCV20 Prescribing Information Respiratory Syncytial Virus (RSV) RSV surges early in 2022, but appears to make early retreat <a style="background-color: rgba(255, 255, 255, 0); font-family: var(--body_typography-font-family); font-size: var(--body_typography-font-size); font-style: var(--body_typography-font-style,normal); font-weight: var(--body_typography-font-weight); letter-spacing: var(--body_typography-letter-spacing);" href="https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/interim-guidance-for-use-of-palivizumab-prophylaxis-to-prevent-hospitalization/" target="_blank" rel="noopener noreferrer">Updated Guidance: Use of Palivizumab Prophylaxis to Prevent Hospitalization From Severe Respiratory Syncytial Virus Infection During the 2022-2023 RSV Season Multiple RSV vaccines in late-stage development show promise in older adults CYPRESS Phase 2b Data on the Efficacy and Immunogenicity of an Ad26.RSV.preF-based RSV Vaccine Why Making a Diagnosis of Respiratory Syncytial Virus Should Matter to Clinicians Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017-2020 A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults Respiratory Syncytial Virus in Older Adults: A Hidden Epidemic. A Report by the National Foundation for Infectious Diseases Respiratory Syncytial Virus (RSV) CDC Factsheet. RSV in Older Adults and Adults with Chronic Medical Conditions Advances in RSV Vaccine Research and Development – A Global Agenda Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study Respiratory Syncytial Virus Infection Respiratory Syncytial Virus in Older Adults: A Hidden Epidemic. A Report by the National Foundation for Infectious Disease [/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

Infectious Disease - Vindico Medical Education